The FDA’s perspective on the approval of HIFU in the USA

For those able to access the February 2016 issue of the AUA News, it carries an interesting article outlining the U.S. Food and Drug Administration’s perspective on exactly why the agency decided to approve two forms of high-intensity focused ultrasound (HIFU) technology for the transrectal ablation of prostate tissue. … READ MORE …

Does your doctor ever thank you for coming to see him or her?

So there was a fascinating article in last October’s issue of Medical Economics that has just been brought to our attention. … READ MORE …

Publication of final data from the TRAPEZE trial

Some 2½ years ago, James presented data from the TRAPEZE trial at the annual meeting of the American Society of Clinical Oncology in Chicago. At the time, we described these data as “unsurprising.” … READ MORE …

Heightened risk for prostate cancer among balding males (redux)

Back in 2014, Zhou et al. reported an association between baldness and risk for diagnosis with aggressive forms of prostate cancer. At the time we noted that this association really needed to be confirmed in other studies. … READ MORE …

Risk for infection(s) from fiducial marker placement

Most of us who have gone through any form of image-guided external beam radiotherapy have had TRUS-guided transrectal placement of gold fiducial markers or radio transponders placed in our prostates. Some who have had salvage radiation have had them placed in the prostate bed. … READ MORE …

Is prostate-specific radiation still of any value in men diagnosed with distant metastases?

In some cancers, debulking of the primary tumor, also called cytoreduction, either with radiation or surgery, has been found to slow progression. Is that true of prostate cancer? … READ MORE …

Extraprostatic extension (EPE) alone is not enough to justify adjuvant radiation

Patrick Walsh and Nathan Laurentschuk have just published an opinion piece in European Urology taking issue with the 2013 AUA/ASTRO recommendation that adjuvant radiation is indicated for men with a pathological finding of extraprostatic extension (EPE, stage pT3a) after surgery, regardless of the surgical margin status. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,367 other followers